Myriad Genetics Inc (MYGN): Alexander Ford , President, MGL of Myriad Genetics Inc sold 18,637 shares on Jun 21, 2016. The Insider selling transaction was reported by the company on Jun 22, 2016 to the Securities and Exchange Commission. The shares were sold at $30.87 per share for a total value of $575,384.81 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 8, 2016, Gary A. King (Exec. VP International Ops) sold 15,000 shares at $39.03 per share price.On Dec 14, 2015, Walter Phd Gilbert (director) sold 5,000 shares at $42.23 per share price.Also, On Dec 9, 2015, S. Louise Phanstiel (director) sold 5,000 shares at $44.00 per share price.On Nov 5, 2015, Heinrich Dreismann (director) sold 60,000 shares at $44.44 per share price.
Myriad Genetics: On Monday, Jun 20, 2016 heightened volatility was witnessed in Myriad Genetics which led to swings in the share price. The shares opened for trading at $30.8 and hit $31.6 on the upside , eventually ending the session at $30.93, with a gain of 2.83% or 0.85 points. The heightened volatility saw the trading volume jump to 10,28,579 shares. The 52-week high of the share price is $46.24 and the company has a market cap of $2,174 M . The 52-week low of the share price is at $30.01.
Company has been under the radar of several Street Analysts.Myriad Genetics is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 34 from a previous price target of $42 . The Rating was issued on May 4, 2016.
Myriad Genetics Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics which provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing or assess a patient’s risk of disease progression and disease recurrence and other which provides testing products and services to the pharmaceutical biotechnology and medical research industries research and development and clinical services for patients. It offers diagnostic tests for various diseases such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer and Vectra DA for rheumatoid arthritis.